- Home
- COCP vs SNSE Comparison
COCP vs SNSE Comparison
Compare COCP & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COCP | SNSE |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 13.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | COCP | SNSE |
|---|---|---|
| Price | $1.05 | $10.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $72.50 |
| AVG Volume (30 Days) | ★ 103.2K | 86.9K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $5.00 |
| 52 Week High | $2.67 | $18.35 |
Technical Indicators
Market Signals| Indicator | COCP | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 49.59 |
| Support Level | $1.03 | $9.32 |
| Resistance Level | $1.19 | $11.51 |
| Average True Range (ATR) | 0.06 | 1.01 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 22.73 | 32.22 |
Price Performance
Historical ComparisonAbout COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).